Table 2 Questions posed to participants for the round table discussions
1 | Should G6PD testing always be done prior to prescribing primaquine? (What does the current WHO recommendation mean for your program?) |
2 | What are the key barriers for introducing routine G6PD testing? (e.g. barriers at decision maker level, at provider level) |
3 | How can we promote G6PD testing prior to primaquine or tafenoquine? (e.g. what evidence is needed to make a case for testing, how can it be funded, what should it cost, what support is needed?) |
4 | What will be the challenges rolling out tafenoquine? |
5 | How would you provide G6PD testing when tafenoquine is rolled out? (E.g. at what level? Who will test? How will the results be recorded? Testing before every episode? Are there areas with high P.v. burden where you believe G6PD testing would not be feasible? If so, what alternatives could be considered?) |
6 | How can we encourage primaquine usage for radical cure? |
7 | How can we improve treatment adherence? (e.g. are there specific issues with adherence in hard to reach populations and how to solve them?) |
8 | What kinds of tests do we need for routine G6PD testing? (e.g. test format, operational characteristics, training involved, cost per test etc.) |